Bio-Thera Solutions Ltd (688177) - Total Assets
Based on the latest financial reports, Bio-Thera Solutions Ltd (688177) holds total assets worth CN¥2.39 Billion CNY (≈ $349.02 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 688177 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Bio-Thera Solutions Ltd - Total Assets Trend (2016–2025)
This chart illustrates how Bio-Thera Solutions Ltd's total assets have evolved over time, based on quarterly financial data. Check 688177 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Bio-Thera Solutions Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Bio-Thera Solutions Ltd's total assets of CN¥2.39 Billion consist of 41.9% current assets and 58.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.6% |
| Accounts Receivable | CN¥164.70 Million | 7.2% |
| Inventory | CN¥312.42 Million | 13.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥218.44 Million | 9.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Bio-Thera Solutions Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Bio-Thera Solutions Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bio-Thera Solutions Ltd's current assets represent 41.9% of total assets in 2025, a decrease from 46.9% in 2016.
- Cash Position: Cash and equivalents constituted 9.6% of total assets in 2025, up from 1.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 13.7% of total assets.
Bio-Thera Solutions Ltd Competitors by Total Assets
Key competitors of Bio-Thera Solutions Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥3.25 Billion |
Bio-Thera Solutions Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.67 | 0.86 | 3.67 |
| Quick Ratio | 0.42 | 0.64 | 3.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-484.66 Million | CN¥-171.31 Million | CN¥981.84 Million |
Bio-Thera Solutions Ltd - Advanced Valuation Insights
This section examines the relationship between Bio-Thera Solutions Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 31.13 |
| Latest Market Cap to Assets Ratio | 0.45 |
| Asset Growth Rate (YoY) | 3.7% |
| Total Assets | CN¥2.29 Billion |
| Market Capitalization | $1.03 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Bio-Thera Solutions Ltd's assets below their book value (0.45x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bio-Thera Solutions Ltd's assets grew by 3.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bio-Thera Solutions Ltd (2016–2025)
The table below shows the annual total assets of Bio-Thera Solutions Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.29 Billion ≈ $334.71 Million |
+3.71% |
| 2024-12-31 | CN¥2.21 Billion ≈ $322.74 Million |
-3.57% |
| 2023-12-31 | CN¥2.29 Billion ≈ $334.67 Million |
+4.93% |
| 2022-12-31 | CN¥2.18 Billion ≈ $318.96 Million |
-16.73% |
| 2021-12-31 | CN¥2.62 Billion ≈ $383.06 Million |
+9.39% |
| 2020-12-31 | CN¥2.39 Billion ≈ $350.19 Million |
+135.93% |
| 2019-12-31 | CN¥1.01 Billion ≈ $148.43 Million |
-0.63% |
| 2018-12-31 | CN¥1.02 Billion ≈ $149.37 Million |
+64.92% |
| 2017-12-31 | CN¥618.94 Million ≈ $90.57 Million |
-12.61% |
| 2016-12-31 | CN¥708.29 Million ≈ $103.65 Million |
-- |
About Bio-Thera Solutions Ltd
Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; POBEVCY to treat patients with metast… Read more